• Philipp Gauckler, Emanuel Zitt, Heinz Regele, Kathrin Eller, Marcus D Säemann, Karl Lhotta, Irmgard Neumann, Michael Rudnicki, Balazs Odler, Andreas Kronbichler, Johannes Zschocke, and Martin Windpessl.
• Department Innere Medizin IV (Nephrologie und Hypertensiologie), Medizinische Universität Innsbruck, Innsbruck, Österreich. philipp.gauckler@i-med.ac.at.
• Wien. Klin. Wochenschr. 2023 Aug 1; 135 (Suppl 5): 638647638-647.

AbstractThe histopathological term focal-segmental glomerulosclerosis comprises different pathogenic processes with the unifying features of a high proteinuria and the name-giving glomerular lesion pattern seen on light microscopy. A differentiation according to the underlying cause into primary, secondary and genetic forms is therefore of utmost importance. The pathogenesis of primary focal-segmental glomerulosclerosis remains unknown but, like minimal-change disease, an autoimmune-mediated process leading to podocyte damage is assumed. Consequently, the unifying term "podocytopathy" is increasingly being used for both entities. Supportive treatment measures to preserve kidney function are important in all subtypes. In contrast, immunosuppressive treatment is only indicated in primary focal-segmental glomerulosclerosis. Steroid-dependence, steroid-resistance and frequently relapsing disease often complicate disease management and necessitate alternative treatment strategies. Here, the Austrian Society of Nephrology (ÖGN) provides consensus recommendations on how to best diagnose and manage patients with focal-segmental glomerulosclerosis.© 2023. The Author(s).

14 keywords...

hide…